CAR-T cell therapy is an innovative and personalized approach to treating cancer that involves genetically engineering a patient's own T cells to recognize and attack cancer cells. In Europe, there are currently two CAR-T cell therapies approved for the treatment of multiple myeloma:
1. Abecma (idecabtagene vicleucel): In March 2021, the European Commission granted conditional marketing authorization to Abecma, a CAR-T cell therapy developed by Bristol Myers Squibb for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody. Abecma is designed to target the B-cell maturation antigen (BCMA), a protein that is highly expressed on the surface of myeloma cells.
2. Tecartus (brexucabtagene autoleucel): In August 2021, the European Commission granted conditional marketing authorization to Tecartus, a CAR-T cell therapy developed by Gilead Sciences for the treatment of relapsed or refractory mantle cell lymphoma in adult patients who have received at least one prior therapy. While not specifically approved for multiple myeloma, Tecartus targets the CD19 antigen, which is expressed on the surface of some myeloma cells. (Rare cases)
It's worth noting that these therapies are highly specialized and are typically administered at specialized treatment centers by teams of experienced healthcare professionals. As with any medical treatment, the decision to pursue CAR-T cell therapy should be made in consultation with a healthcare provider who can help determine if it's an appropriate option based on the patient's individual circumstances.
Below are names of some specialized treatment centers in Europe that offer CAR-T cell therapy for multiple myeloma:
- University College London Hospitals NHS Foundation Trust, London, UK
- The Christie NHS Foundation Trust, Manchester, UK
- King's College Hospital NHS Foundation Trust, London, UK
- University Hospital Würzburg, Würzburg, Germany
- University Hospital Heidelberg, Heidelberg, Germany
- Hospital Clínic de Barcelona, Barcelona, Spain
- University Hospital of Zurich, Zurich, Switzerland
- Gustave Roussy Cancer Campus, Villejuif, France
- Assistance Publique-Hôpitaux de Paris, Paris, France
- Leiden University Medical Center, Leiden, Netherlands
It's important to note that this is not an exhaustive list and there may be other specialized treatment centers in Europe that offer CAR-T cell therapy for multiple myeloma.
CAR-T cell therapy in Israel
CAR-T for Leukemia and Lymphoma in Israel
CAR-T for Myeloma in Israelbr> CAR-T cell therapy for leukemia and non-Hodgkin's lymphoma (NHL) in Europe
CAR-T Cell Therapy for Blood Cancers: A Global Overview